3.31

2.36% -0.08

After Hours: 3.38 0.07 +2.11%

Lexeo Therapeutics Inc (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc stock is traded at $3.31, with a volume of 1.01M. It is down -2.36% in the last 24 hours and down -35.48% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Previous Close:

$3.39

Open:

$3.4

24h Volume:

1.01M

Relative Volume:

1.03

Market Cap:

$271.71M

Revenue:

$531.00K

Net Income/Loss:

$-99.96M

P/E Ratio:

-1.5101

EPS:

-2.1919

Net Cash Flow:

$-98.96M

1W Performance:

-21.19%

1M Performance:

-35.48%

6M Performance:

-42.13%

1Y Performance:

-49.08%

1-Day Range:

$3.27

$3.455

1-Week Range:

$3.27

$4.335

52-Week Range:

$3.27

$10.99

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(212) 547-9879

Address

345 PARK AVENUE SOUTH, NEW YORK

Employee

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

LXEO's Discussions on Twitter

Compare LXEO vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXEO Lexeo Therapeutics Inc	3.31	271.71M	531.00K	-99.96M	-98.96M	-2.1919
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Raymond James	Strong Buy
Nov-20-25	Initiated	Cantor Fitzgerald	Overweight
Oct-15-25	Initiated	Guggenheim	Buy
Jul-31-25	Initiated	Oppenheimer	Outperform
Jun-13-24	Initiated	Robert W. Baird	Outperform
Jun-06-24	Initiated	H.C. Wainwright	Buy
Nov-28-23	Initiated	Chardan Capital Markets	Buy
Nov-28-23	Initiated	JP Morgan	Overweight
Nov-28-23	Initiated	Leerink Partners	Outperform
Nov-28-23	Initiated	RBC Capital Mkts	Outperform
Nov-28-23	Initiated	Stifel	Buy

View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

06:15 AM

The week in pharma: action, reaction and insight – week to September 25, 2026 - The Pharma Letter

06:15 AM

Sep 25, 2026

LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill

Sep 25, 2026

Sep 23, 2026

Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners - Moomoo

Sep 23, 2026

Leerink Partners maintains Outperform rating on Lexeo Therapeutics, $15 price target - TradingView

Sep 23, 2026

Lexeo Therapeutics expands position in Friedreich’s ataxia - BioWorld News

Sep 23, 2026

Lexeo gains access to Apertura’s gene therapy capsid By Investing.com - Investing.com India

Sep 23, 2026